Incidence and Distribution of Bone Metastases

  • R. Coleman
Conference paper

Abstract

In the Western world one in three people will develop a malignancy, and of these two-thirds can be expected ultimately to die of their cancer. Figures from 1980 for the European Community countries estimate 1 220 000 incident cases of cancer and 750 000 deaths. Death from cancer is usually due to the development of metastases, and the skeleton is the organ most frequently involved.

Keywords

Lymphoma Estrogen Iodine Radionuclide Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Galasko CSB (1981) The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert AH (eds) Bone metastasis. Hall, Boston, pp 49–63Google Scholar
  2. 2.
    Scher HI, Yagoda A (1987) Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am. J. Med. 82 [Suppl 2A]: 6–28PubMedCrossRefGoogle Scholar
  3. 3.
    Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br. J. Cancer 55: 61–66PubMedCrossRefGoogle Scholar
  4. 4.
    Dorudi S, Hart I (1993) Mechanisms underlying invasion and metastasis. Curr Opin Oncol 5: 130–135PubMedGoogle Scholar
  5. 5.
    Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumour emboli labelled with 125I-5-iodo-2’-deoxyuridine. J Natl Cancer Inst 45: 773–782.PubMedGoogle Scholar
  6. 6.
    Boyce BF (1991) Normal bone remodelling and its disruption in metastatic bone disease. In: Rubens RD, Fogelman I (eds) Bone metastasis - diagnosis and treatment. Springer, Berlin, Heidelberg, New York, pp 11–30Google Scholar
  7. 7.
    Ewing J (1928) Metastasis. In: Neoplastic diseases. A textbook on tumours. Saunders, Philadelphia, pp 77–89Google Scholar
  8. 8.
    Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet I: 571–573Google Scholar
  9. 9.
    Batson OV (1942) The role of the vertebral veins in metastatic processes. Ann Intern Med 16: 38–45Google Scholar
  10. 10.
    Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340: 685–689PubMedCrossRefGoogle Scholar
  11. 11.
    Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC et al. (1987) Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 29: 1093–1096CrossRefGoogle Scholar
  12. 12.
    Mundy GR, De Martino S, Rowe DW (1981) Collagen and collagen-derived fragments are chemotactic for tumour cells. J. Clin. Invest. 68: 1102–1105PubMedCrossRefGoogle Scholar
  13. 13.
    Orr FW, Varani J, Gondek MD, Ward PA, Mundy GR (1980) Partial characterization of a bone-derived chemotactic factor for tumour cells. Am J. Pathol. 99: 43–52PubMedGoogle Scholar
  14. 14.
    Bundred NJ, Ratcliffe WA, Walker RA, Coley S, Morrison JM, Ratcliffe JG (1991) Parathyroid hormone related protein and hypercalcaemia in breast cancer. Br. Med. J. 303: 1506–1509CrossRefGoogle Scholar
  15. 15.
    Chackal-Roy M, Niemeyer C, Moore M, Zetter BR (1989) Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest. 84: 43–50PubMedCrossRefGoogle Scholar
  16. 16.
    Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, Sobel ME (1988) Altered expression of nm23, a gene associated with low tumour metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res 48: 6550–6554PubMedGoogle Scholar
  17. 17.
    Henneesy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ (1991) Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 83: 281–285CrossRefGoogle Scholar
  18. 18.
    Nesbit RM, Baum WC (1984) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JNCI 68: 507–517Google Scholar
  19. 19.
    Jacobs SC, Pikna D, Lawson RK (1979) Prostatic osteoblastic factor. Invest. Urol. 17: 195–198PubMedGoogle Scholar
  20. 20.
    Brookes M (1971) Blood vessels in bone marrow. In: Brookes M (ed) The blood supply of bone. An approach to bone biology. Butterworth, London, pp 67–91Google Scholar
  21. 21.
    Boxer DI, Todd CEC, Coleman R, Fogelman I (1989) Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 30: 1318–1320PubMedGoogle Scholar
  22. 22.
    Coleman RE, Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19: 79–103PubMedCrossRefGoogle Scholar
  23. 23.
    Koutsilieris M, Rabbini SA, Bennett HPJ et al. (1987) Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J. Clin. Invest. 80: 941–946PubMedCrossRefGoogle Scholar
  24. 24.
    Galasko CSB (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature 263: 507–508PubMedCrossRefGoogle Scholar
  25. 25.
    Dodwell D, Howell A (1991) The systemic treatment of bone metastases. In: Rubens RD, Fogelman I (eds) Bone metastases - diagnosis and treatment. Springer, Berlin, Heidelberg, New York, pp 121–148Google Scholar
  26. 26.
    Charbord P, L’héritier C, Cukerstein W, Lumbroso J, Tubiana M (1977) Radio- iodine treatment in differentiated thyroid carcinomas. Treatment of first local recurrences and of bone and lung metastases. Ann Radiol 20: 783–786PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • R. Coleman

There are no affiliations available

Personalised recommendations